Otsuka has claimed FDA approval for its IgA nephropathy (IgAN) therapy Voyxact, joining an increasingly crowded market and beating rival Vera Therapeutics to the punch. Anti-APRIL antibody Voyxact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback